[go: up one dir, main page]

WO2014210369A3 - Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents - Google Patents

Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents Download PDF

Info

Publication number
WO2014210369A3
WO2014210369A3 PCT/US2014/044422 US2014044422W WO2014210369A3 WO 2014210369 A3 WO2014210369 A3 WO 2014210369A3 US 2014044422 W US2014044422 W US 2014044422W WO 2014210369 A3 WO2014210369 A3 WO 2014210369A3
Authority
WO
WIPO (PCT)
Prior art keywords
reversal
cysteine
inactivated
combinations
neuromuscular blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/044422
Other languages
French (fr)
Other versions
WO2014210369A2 (en
Inventor
Paul M. Heerdt
John J. Savarese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of WO2014210369A2 publication Critical patent/WO2014210369A2/en
Publication of WO2014210369A3 publication Critical patent/WO2014210369A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

We provide methods and kits to reverse neuromuscular block caused by a cysteine-inactivated neuromuscular blocking drug, comprising administering to said subject a combination of a cysteine-like agent and an acetylcholinesterase inhibitor. An antimuscarinic agent may also be administered to said subject.
PCT/US2014/044422 2013-06-28 2014-06-26 Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents Ceased WO2014210369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361841211P 2013-06-28 2013-06-28
US61/841,211 2013-06-28

Publications (2)

Publication Number Publication Date
WO2014210369A2 WO2014210369A2 (en) 2014-12-31
WO2014210369A3 true WO2014210369A3 (en) 2015-05-28

Family

ID=52142838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/044422 Ceased WO2014210369A2 (en) 2013-06-28 2014-06-26 Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents

Country Status (1)

Country Link
WO (1) WO2014210369A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198628A1 (en) * 2020-10-17 2022-04-21 Cornell University Methods for controlling and predicting recovery after nmba administration
WO2024149360A1 (en) * 2023-01-12 2024-07-18 西藏海思科制药有限公司 Biquaternary ammonium salt compound and pharmaceutical application thereof
WO2025140279A1 (en) * 2023-12-25 2025-07-03 上海森辉医药有限公司 Quaternary ammonium compound and pharmaceutical use thereof
WO2025140288A1 (en) * 2023-12-25 2025-07-03 上海森辉医药有限公司 Tetrahydroisoquinoline and pharmaceutical use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187789B1 (en) * 1997-03-25 2001-02-13 Glaxo Wellcome Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers
US8148398B2 (en) * 2006-12-06 2012-04-03 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187789B1 (en) * 1997-03-25 2001-02-13 Glaxo Wellcome Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers
US8148398B2 (en) * 2006-12-06 2012-04-03 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CALDWELL ET AL.: "Clinical limitations of acetylcholinesterase antagonists", JOURNAL OF CRITICAL CARE, vol. 24, 2009, pages 21 - 28, XP025969363, DOI: doi:10.1016/j.jcrc.2008.08.003 *

Also Published As

Publication number Publication date
WO2014210369A2 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders
MX365939B (en) Nuclear transport modulators and uses thereof.
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
NZ702744A (en) D-amino acid compounds for liver disease
HK1198869A1 (en) Combination treatments for hepatitis c
HK1223319A1 (en) Methods for treating or preventing ophthalmological conditions
HRP20250119T1 (en) A kdm1a inhibitor and its use in therapy
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
MX2019007956A (en) SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT.
EA201400119A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2012121977A3 (en) Dodecafluoropentane emulsion as a stroke and ischemia therapy
BR112015019587A2 (en) combinations comprising maba compounds and corticosteroids
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2015014097A (en) CANCER TREATMENT USING COMBINED THERAPIES OF COENZIMA Q10.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2019008817A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof.
WO2013117744A3 (en) Methods of treating fibrosis
MX2016006318A (en) 7-BENCIL-4- (2-METHYLBENCIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PIR IDO [3,4-E] PIRIMIDIN-5 (1H) -ONA, SALTS OF THE SAME AND METHODS OF USE.
IN2013MU00711A (en)
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
CL2013003700A1 (en) Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder.
CA3010788A1 (en) Methods of administering vasopressors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14817922

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14817922

Country of ref document: EP

Kind code of ref document: A2